We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technology



There is a cure for autoimmune diabetes

What We Do

We develop therapies using our in-licensed substances GAD and GABA for the prevention or treatment of diabetes and other serious inflammatory diseases

Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development. Diamyd Medical’s shares are traded on Nasdaq First North, ticker DMYD B.

Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product.



425 million people worldwide suffer from diabetes. 10-20 percent have autoimmune diabetes (type 1 diabetes and LADA). There is currently no available preventive treatment or cure.



Diamyd Medical tackles autoimmune diabetes (type 1 diabetes and LADA) on three fronts: drug development, stem cell and medical technology. Five clinical trials are ongoing, combining the diabetes vaccine Diamyd® with various other immunomodulatory compounds including GABA.


Diamyd Medical is a cost-efficient and flexible company with substantial experience of pharmaceutical and technical development. Parts of the operations are outsourced to qualified partners with expert knowledge while the company employees manage and implement clinical and preclinical development, regulatory affairs, production and business development.


So far, patient enrollment for DIAGNODE-2 has exceeded our expectations.

Ulf Hannelius
President and CEO, Diamyd Medical AB